[HTML][HTML] WY14, 643, a peroxisome proliferator-activated receptor α (PPARα) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in …
CJ Chou, M Haluzik, C Gregory, KR Dietz… - Journal of Biological …, 2002 - ASBMB
WY14, 643 is a specific peroxisome proliferator-activated receptor α (PPARα) agonist with
strong hypolipidemic effects. Here we have examined the effect of WY14, 643 in the A-ZIP/F-
1 mouse, a model of severe lipoatrophic diabetes. With 1 week of treatment, all doses of
WY14, 643 that were tested normalized serum triglyceride and fatty acid levels. Glucose and
insulin levels also improved but only with high doses and longer treatment duration. WY14,
643 reduced liver and muscle triglyceride content and increased levels of mRNA encoding …
strong hypolipidemic effects. Here we have examined the effect of WY14, 643 in the A-ZIP/F-
1 mouse, a model of severe lipoatrophic diabetes. With 1 week of treatment, all doses of
WY14, 643 that were tested normalized serum triglyceride and fatty acid levels. Glucose and
insulin levels also improved but only with high doses and longer treatment duration. WY14,
643 reduced liver and muscle triglyceride content and increased levels of mRNA encoding …